The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Iberdomide plus dexamethasone for heavily pretreated multiple myeloma
After demonstrating marked synergy with several standard myeloma treatments in preclinical investigations, iberdomide, a novel oral cereblon E3 ligase modulator (CELMoD), was investigated in different treatment combinations in a Phase I/II study of patients with relapsed/refractory multiple myeloma. Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, Netherlands, shares the findings from the iberdomide plus dexamethasone arm of the ongoing CC-220-MM-001 trial (NCT02773030). After determination of the recommended Phase II dose of iberdomide when used in combination with dexamethasone, a dose expansion phase was initiated in triple-class exposed patients. At the time of data cut off, over 100 patients had been treated with iberdomide plus dexamethasone, with a median follow-up of 7.69 months. The overall response rate was 26.2%, with a clinical benefit rate of 36.4%. The combination was well tolerated, and adverse events were manageable with dose interruptions and reductions. Occurrence of grade 3-4 non-hematologic treatment emergent adverse events was infrequent. These results support the continued investigation of iberdomide-based combinations in myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
